237 related articles for article (PubMed ID: 35777418)
1. Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Lopez-Morinigo JD; Leucht S; Arango C
Pharmacopsychiatry; 2022 Sep; 55(5):233-245. PubMed ID: 35777418
[TBL] [Abstract][Full Text] [Related]
2. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T; Ikuta T; Matsuda Y; Sakuma K; Okuya M; Nomura I; Hatano M; Iwata N
Mol Psychiatry; 2022 Feb; 27(2):1136-1144. PubMed ID: 34642461
[TBL] [Abstract][Full Text] [Related]
6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
7. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Oh S; Byeon SJ; Chung SJ
J Psychopharmacol; 2022 Sep; 36(9):1041-1050. PubMed ID: 35695641
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
11. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
[TBL] [Abstract][Full Text] [Related]
13. Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia.
Crump CJ; Good ME; Abuelazm H; El-Mallakh RS
Expert Opin Pharmacother; 2023 Jun; 24(9):1039-1052. PubMed ID: 37102321
[TBL] [Abstract][Full Text] [Related]
14. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Bitter I; Czobor P; Dossenbach M; Volavka J
Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
[TBL] [Abstract][Full Text] [Related]
16. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Srisurapanont M; Likhitsathian S; Suttajit S; Maneeton N; Maneeton B; Oon-Arom A; Suradom C
Drug Alcohol Depend; 2021 Feb; 219():108467. PubMed ID: 33385693
[TBL] [Abstract][Full Text] [Related]
18. New generation antipsychotics for first episode schizophrenia.
Rummel C; Hamann J; Kissling W; Leucht S
Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps.
Jeun KJ; Kamal KM; Adhikari K; Nolfi DA; Ashraf MN; Zacker C
J Manag Care Spec Pharm; 2024 Feb; 30(2):183-199. PubMed ID: 38308625
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]